Although emerging evidence suggests that the location of mutations may influence clinical outcomes [16,17], no discernible pattern has been observed indicating which location of the BRCA1/2 mutation influences clinical outcomes in ovarian cancer patients with BRCA1 and BRCA2 mutations. Here, BRCA2 is linked to ovarian carcinoma.